Quack AI
NEAR Protocol
Lighter
Bitway
Pearl
Quantus
Sui
- AstraZeneca is facing two COVID-19 vaccine lawsuits in London.
- The company released the Q2-2023 report on 28 July 2023.
- AZN stock slid -0.16% during the intraday session. It is trading at $69.07.
AstraZeneca Faces Covid-19 Vaccine Lawsuits In London.
Today, the Anglo-Swedish pharmaceutical giant is under legal investigation. It is facing two lawsuits related to its COVID-19 vaccine in The High Court of Justice in London by Anish Tailor.
Anish Taior’s wife died in March 2021 after she received her first dose of the AstraZeneca vaccine. It restricted vaccine use for users below 40 years of age because of a minimal risk of blood clotting.
AstraZeneca stock price witnessed a sudden spike in the of approximately 19% in mid-March 2023. It was at a low of $63.89, and then surged and halted on 25 April 2023 while achieving an annual high at $76.56 resistance level. The AZN stock surged in an uptrend while following the trendline. This whole event reflects the bulls are dominating the price action at that period.
The AZN stock price is experiencing a significant pullback after achieving an annual high. The price formed support at $71.23 after revealing a one-month consolidation between the $75.66 and $73.89 range. However, it displayed a double top at the $75.75 level on 16 June 2023. The annual high was a first top.
The AZN stock price experienced an enormous fall of roughly 15% and formed support at 64.55 after the double-top incident. It bounced back, retested the previous February resistance level, and surged further towards the $71.50 level.
AstraZeneca Released Q2-2023 Report
AstraZeneca plc released its Q2-2023 financial earning report on 28 July 2023. It revealed optimistic results with a surprise of $0.087. The reported EPS (earning per share) was $1.07, and the estimated forecast was $0.98.
The reported second-quarter revenue was $11.41 Billion. It surpassed the $11.01 Billion estimated revenue forecast by $403.74 Million.
The current market sentiment of AZN stock reveals a slight bullish trend according to the weekly return of 0.22%. If this upward momentum sustains or increases, the price might surge. It may retest the previous resistance level of $70.30.
On the contrary, if the bears snatch control, the possibility of a downtrend would be high. The price might melt towards $66.00.
Will AZN Retest 70 Mark?
The RSI (relative strength index) has been dragging along the 50 mark since 20 July 2023. Now, it scored 45.04 during the intraday trading session. It neither reflects weakness nor strength, and the price might consolidate.
The CMF (Chaikin Money Flow) score is 0.10 during the intraday session. It demonstrates the slight participation of buyers in the market.
Conclusion
Japan waves approval for AstraZeneca’s prostate cancer drug on 24 August. It’s good news for the firm, but recent COVID-19 lawsuits might trouble in the future.
Disclaimer
The information provided in this article. Including the views and opinions expressed by the author or any individuals mentioned, is intended for informational purposes only. It is important to note that the article does not provide financial or investment advice. Investing or trading in cryptocurrency assets carries inherent risks and can result in financial loss.
